Fisetin for Carpal Tunnel Syndrome

Phase-Based Progress Estimates
Mayo Clinic in Rochester, Rochester, MN
Carpal Tunnel Syndrome+1 More
Fisetin - Drug
All Sexes
What conditions do you have?

Study Summary

This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).

Eligible Conditions

  • Carpal Tunnel Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Carpal Tunnel Syndrome

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline, 180 days

Baseline, 180 days
percent decrease in blood markers of cellular senescence in long-term
Baseline, 60 days
Change in CTS symptoms
percent decrease in blood markers of cellular senescence, e.g., p16, IL-6, IL-15, TNF, PAI-1, ICAM-1, and additional exploratory, novel assays

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Carpal Tunnel Syndrome

Trial Design

1 Treatment Group

Carpal Tunnel Syndrome
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Fisetin · No Placebo Group · Phase 2

Carpal Tunnel Syndrome
Experimental Group · 1 Intervention: Fisetin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 180 days
Closest Location: Mayo Clinic in Rochester · Rochester, MN
Photo of Rochester 1Photo of Rochester 2Photo of Rochester 3
2021First Recorded Clinical Trial
5 TrialsResearching Carpal Tunnel Syndrome
507 CompletedClinical Trials

Who is running the clinical trial?

Peter C. Amadio, M.D.Lead Sponsor
Peter C AmadioPrincipal InvestigatorMayo Clinic

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a classic or probable carpal tunnel syndrome on a hand diagram.
You have a clinical diagnosis of carpal tunnel syndrome.
You have symptoms of numbness or tingling in at least two digits on one hand that include thumb, index, long, or radial border of ring finger.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.